SG11202103451YA - Compounds and compositions for treating conditions associated with apj receptor activity - Google Patents

Compounds and compositions for treating conditions associated with apj receptor activity

Info

Publication number
SG11202103451YA
SG11202103451YA SG11202103451YA SG11202103451YA SG11202103451YA SG 11202103451Y A SG11202103451Y A SG 11202103451YA SG 11202103451Y A SG11202103451Y A SG 11202103451YA SG 11202103451Y A SG11202103451Y A SG 11202103451YA SG 11202103451Y A SG11202103451Y A SG 11202103451YA
Authority
SG
Singapore
Prior art keywords
compositions
compounds
conditions associated
receptor activity
treating conditions
Prior art date
Application number
SG11202103451YA
Other languages
English (en)
Inventor
Haifeng Tang
Michael Hanson
Sarah Boyce
Zhe Nie
Original Assignee
Annapurna Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annapurna Bio Inc filed Critical Annapurna Bio Inc
Publication of SG11202103451YA publication Critical patent/SG11202103451YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11202103451YA 2018-10-05 2019-10-04 Compounds and compositions for treating conditions associated with apj receptor activity SG11202103451YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862742218P 2018-10-05 2018-10-05
PCT/US2019/054880 WO2020073011A1 (en) 2018-10-05 2019-10-04 Compounds and compositions for treating conditions associated with apj receptor activity

Publications (1)

Publication Number Publication Date
SG11202103451YA true SG11202103451YA (en) 2021-05-28

Family

ID=68296866

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103451YA SG11202103451YA (en) 2018-10-05 2019-10-04 Compounds and compositions for treating conditions associated with apj receptor activity

Country Status (18)

Country Link
US (2) US11471455B2 (pt)
EP (2) EP4364798A2 (pt)
JP (1) JP2022508648A (pt)
KR (1) KR20210125471A (pt)
CN (1) CN113490668A (pt)
AR (1) AR116687A1 (pt)
AU (2) AU2019353144B2 (pt)
BR (1) BR112021006488A2 (pt)
CA (1) CA3115472A1 (pt)
DK (1) DK3860998T3 (pt)
EA (1) EA202190952A1 (pt)
FI (1) FI3860998T3 (pt)
IL (1) IL282021A (pt)
MX (1) MX2021003904A (pt)
PT (1) PT3860998T (pt)
RS (1) RS65335B1 (pt)
SG (1) SG11202103451YA (pt)
WO (1) WO2020073011A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021006488A2 (pt) 2018-10-05 2021-07-06 Annapurna Bio Inc compostos e composições para o tratamento de condições associadas com atividade do receptor apj
CN112724089B (zh) * 2021-01-05 2022-08-26 烟台皓元生物医药科技有限公司 一种2-氨基-3-溴-6-氯吡嗪的合成工艺
EP4367086A2 (en) * 2021-07-06 2024-05-15 University of Georgia Research Foundation, Inc. Compositions and methods for treating and preventing viral infections
WO2024099382A1 (en) 2022-11-10 2024-05-16 Annapurna Bio, Inc. Salts and solid forms of a compound having apj receptor activity

Family Cites Families (275)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4633956Y1 (pt) 1967-06-09 1971-11-24
JPS5959330U (ja) 1982-10-13 1984-04-18 斉藤　晃正 通気性防水部材
JPS614960A (ja) 1984-06-19 1986-01-10 Fuji Photo Film Co Ltd 分析試薬および多層化学分析要素
CA2061159A1 (en) 1991-02-26 1992-08-27 Michael A. Poss Imidazole and benzimidazole derivatives
JPH04346987A (ja) 1991-05-23 1992-12-02 Nippon Soda Co Ltd イミダゾピラジン誘導体及びその電子写真感光体としての利用
DE4129603A1 (de) 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5234923A (en) 1991-12-16 1993-08-10 E. R. Squibb & Sons, Inc. Substitute indole and benzimidazole derivatives
EP0630241A1 (en) 1992-03-20 1994-12-28 The Wellcome Foundation Limited Indole derivatives with antiviral activity
JP3383820B2 (ja) 1993-06-02 2003-03-10 独立行政法人産業技術総合研究所 有機非線形光学材料
DE4330959A1 (de) 1993-09-09 1995-03-16 Schering Ag Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
DE4338770A1 (de) 1993-11-12 1995-05-18 Matthias Dr Lehr Indol-2-alkansäuren und ihre Derivate als Hemmstoffe der Phospholipase A¶2¶
US5482960A (en) 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
JPH08157461A (ja) 1994-12-07 1996-06-18 Sankyo Co Ltd スルホン誘導体
CA2224103A1 (en) 1995-06-07 1996-12-19 Sugen, Inc. Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
US5751787A (en) 1996-09-05 1998-05-12 Nanoptics, Inc. Materials and methods for improved radiography
DK0948495T3 (da) 1996-11-19 2004-06-01 Amgen Inc Aryl- og heteroarylsubstitueret, kondenseret pyrrol som antiinflammatoriske midler
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
CA2291647A1 (en) 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU1124399A (en) 1997-10-28 1999-05-17 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
ID26123A (id) 1998-02-25 2000-11-23 Genetics Inst Penghambat-penghambat phospholipase a2
EA003876B1 (ru) 1998-02-25 2003-10-30 Дженетикс Инститьют, Ллс Ингибиторы фосфолипазных ферментов
JP2002504539A (ja) 1998-02-25 2002-02-12 ジェネティックス・インスチチュート・インコーポレーテッド ホスホリパーゼ酵素の阻害剤
JP2002510623A (ja) 1998-04-02 2002-04-09 メルク エンド カムパニー インコーポレーテッド 抗糖尿病薬
US6534503B1 (en) 1998-04-28 2003-03-18 Lion Bioscience Ag Melanocortin receptor-3 ligands to treat sexual dysfunction
AU4981199A (en) 1998-07-08 2000-02-01 Gregory N. Beatch Compositions and methods for modulating sexual activity
AU1738900A (en) 1998-11-19 2000-06-05 Nortran Pharmaceuticals Inc. Serotonin ligands as pro-erectile compounds
JP4221129B2 (ja) 1999-02-15 2009-02-12 富士フイルム株式会社 含窒素ヘテロ環化合物、有機発光素子材料、有機発光素子
WO2001021634A1 (en) 1999-09-21 2001-03-29 Lion Bioscience Ag Benzimidazole derivatives and combinatorial libraries thereof
CA2387351C (en) 1999-10-19 2009-09-08 Merck & Co., Inc. Indole derivatives as tyrosine kinase inhibitors
ES2235970T3 (es) 1999-10-19 2005-07-16 MERCK & CO. INC. Inhibidores de tirosina quinasa.
ATE311385T1 (de) 1999-10-27 2005-12-15 Novartis Pharma Gmbh Thiazol und imidazo(4,5-b)pyridin verbindungen und ihre verwendung als pharmazeutika
IL149887A0 (en) 1999-12-22 2002-11-10 Metabasis Therapeutics Inc Novel bisamidate phosphonate prodrugs
CZ20022353A3 (cs) 2000-01-07 2003-02-12 Universitaire Instelling Antwerpen Deriváty purinu, způsob jejich přípravy a jejich použití
EE05515B1 (et) 2000-01-14 2012-02-15 Schering@Aktiengesellschaft 1 2 diarlbensimidasoolid mikrogliia aktivatsiooniga seotud haiguste raviks
US20030225036A1 (en) 2000-03-20 2003-12-04 Aleksandr Kolesnikov Non-amidine containing protease inhibitors
WO2002009702A2 (en) 2000-07-28 2002-02-07 Inspire Pharmaceuticals, Inc. Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
EP1311502A1 (en) 2000-08-17 2003-05-21 Celltech R&D Limited Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders
PT1315492E (pt) 2000-09-06 2008-10-01 Ortho Mcneil Pharm Inc Utilização de pirazoles substituídos para o tratamento de alergias
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
AU2002221239A1 (en) 2000-12-07 2002-06-18 Astrazeneca Ab Therapeutic benzimidazole compounds
CA2431166A1 (en) 2000-12-08 2002-06-13 Ortho-Mcneil Pharmaceutical, Inc. Indazolyl-substituted pyrroline compounds as kinase inhibitors
WO2002076960A1 (en) 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transition metal mediated process
US20030109714A1 (en) 2001-03-22 2003-06-12 Neil Wishart Transition metal mediated process
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
DE10135050A1 (de) 2001-07-09 2003-02-06 Schering Ag 1-Ary1-2-N-, S- oder O-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
US6927293B2 (en) 2001-08-30 2005-08-09 Merck & Co., Inc. Tyrosine kinase inhibitors
US6740649B2 (en) 2001-09-17 2004-05-25 Bristol-Myers Squibb Company Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF- α converting enzyme (TACE)
EP1442028A4 (en) 2001-11-06 2009-11-04 Bristol Myers Squibb Co SUBSTITUTED ACID DERIVATIVES, WHICH APPRECIATE AS ANTIDIBILICS AND AGENTS AGAINST OBESITAS, AND METHODS
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
US7632955B2 (en) 2001-12-13 2009-12-15 National Health Research Institutes Indole compounds
US7244847B2 (en) 2002-02-06 2007-07-17 Isis Pharmaceuticals, Inc. Benzimidazole compounds
DE10207843A1 (de) 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
GB0206860D0 (en) 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
NZ535748A (en) 2002-04-12 2007-06-29 Pfizer Use of EP4 receptor ligands in the treatment of IL-6 involved diseases
AU2003225295A1 (en) 2002-05-08 2003-11-11 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
US6951881B2 (en) 2002-05-10 2005-10-04 Wyeth (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands
ES2312785T3 (es) 2002-06-05 2009-03-01 Janssen Pharmaceutica Nv Pirrolinas sustituidas utiles como inhibidores de quinasa.
US20050282733A1 (en) 2002-06-27 2005-12-22 Prins Johannes B Differentiation modulating agents and uses therefor
EP1388541A1 (en) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
JP4695395B2 (ja) 2002-12-13 2011-06-08 ニューロジェン・コーポレーション 疼痛治療用の併用療法
EP1581539A4 (en) 2003-01-03 2007-09-19 Bristol Myers Squibb Co NEW TYROSINE KINASE HEMMER
US7459454B2 (en) 2003-03-21 2008-12-02 Smithkline Beecham Corporation Aminopyrazine derivatives and compositions
US20060035945A1 (en) 2003-05-30 2006-02-16 Giorgio Attardo Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
ES2228267B1 (es) 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2222832B1 (es) 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2228268B1 (es) 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
JP2007505118A (ja) 2003-09-10 2007-03-08 メルク　エンド　カムパニー　インコーポレーテッド アンドロゲン受容体調節剤としての１７−複素環−４−アザステロイド誘導体
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
WO2005028624A2 (en) 2003-09-15 2005-03-31 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
US7566732B2 (en) 2003-10-28 2009-07-28 Rigel Pharmaceuticals, Inc. Rhodanine compositions for use as antiviral agents
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
JPWO2005054213A1 (ja) 2003-12-02 2007-12-06 塩野義製薬株式会社 ペルオキシソーム増殖活性化受容体アゴニスト活性を有するイソキサゾール誘導体
US7791047B2 (en) 2003-12-12 2010-09-07 Semequip, Inc. Method and apparatus for extracting ions from an ion source for use in ion implantation
WO2005065686A1 (en) 2004-01-07 2005-07-21 Adipogen Pharmaceuticals Pty Limited Differentiation modulating agents and uses therefor
WO2005108370A1 (ja) 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
JP2007533753A (ja) 2004-04-23 2007-11-22 タケダ サン ディエゴ インコーポレイテッド インドール誘導体及びキナーゼ阻害剤としてのその使用
WO2005112932A2 (en) 2004-05-07 2005-12-01 Exelixis, Inc. Raf modulators and methods of use
WO2005118580A2 (en) 2004-05-12 2005-12-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Tricyclic compounds as inhibitors of the hypoxic signaling pathway
JP5026963B2 (ja) 2004-06-22 2012-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド カルシウムチャネル調整用の複素環誘導体
BRPI0511834A (pt) 2004-07-14 2008-01-08 Ptc Therapeutics Inc métodos por tratar hepatite c
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
ES2246721B1 (es) 2004-08-10 2007-03-16 Laboratorios Del Dr. Esteve, S.A. Compuestos indolicos sustituidos, su preparacion y su uso como medicamentos.
EP1632491A1 (en) 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituted indole compounds and their use as 5-HT6 receptor modulators
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CA2583152A1 (en) 2004-10-21 2006-04-27 Pfizer Inc. Inhibitors of hepatitis c virus protease, and compositions and treatments using the same
CN101048410B (zh) 2004-10-29 2010-06-23 泰博特克药品有限公司 抑制hiv的双环嘧啶衍生物
US20100093767A1 (en) 2004-12-03 2010-04-15 Takeda San Diego, Inc. Mitotic Kinase Inhibitors
WO2007106436A2 (en) 2006-03-10 2007-09-20 Mallinckrodt Inc. Photoactive compounds and compositions and uses thereof
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
US20060156486A1 (en) 2005-01-14 2006-07-20 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
EP1853255A4 (en) 2005-02-22 2009-07-08 Gemin X Pharmaceuticals Canada METHODS FOR TREATING ARTHRITIS USING TRIHETEROCYCLIC COMPOUNDS
EP1702915A1 (en) 2005-03-14 2006-09-20 Cephalon France Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation
DE102005012872A1 (de) 2005-03-19 2006-09-28 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Pyrrolidino-benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102005012873B4 (de) 2005-03-19 2007-05-03 Sanofi-Aventis Deutschland Gmbh Aminocarbonyl substituierte 8-N-Benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102005012875B4 (de) 2005-03-19 2006-11-16 Sanofi-Aventis Deutschland Gmbh Verwendung von Amino substituierten 8-N-Benzimidazolen
US20060229355A1 (en) 2005-04-08 2006-10-12 The Regents Of The University Of California 3.3'-Diindolylmethane compositions inhibit angiogenesis
WO2006117314A2 (en) 2005-04-30 2006-11-09 Boehringer Ingelheim International Gmbh Novel piperidin- substituted indoles and their use as ccr-3 modulators
JP2007056213A (ja) 2005-08-26 2007-03-08 Fujifilm Corp 焼結含油軸受油用組成物、並びにそれを用いた軸受け装置及び摺動部材
KR20080063288A (ko) 2005-09-30 2008-07-03 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규 융합 피롤 유도체
CN101287707A (zh) 2005-10-13 2008-10-15 德福根有限公司 激酶抑制剂
CA2626961A1 (en) 2005-11-03 2007-05-18 Ilypsa, Inc. Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors
CA2627043A1 (en) 2005-11-03 2007-05-18 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-a2 inhibitors
AU2006331882A1 (en) 2005-12-21 2007-07-05 Schering Corporation Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists
CA2636007A1 (en) 2006-01-13 2007-07-26 Wyeth Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors
JP2009523732A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎の治療方法
NZ570625A (en) 2006-02-10 2011-10-28 Biomarin Iga Ltd Treatment of duchenne muscular dystrophy
WO2007102126A2 (en) 2006-03-07 2007-09-13 The Procter & Gamble Company Compositions for oxidatively dyeing keratin fibers and methods for using such compositions
EP1996183A4 (en) 2006-03-20 2010-04-14 Spinifex Pharm Pty Ltd METHOD FOR THE TREATMENT OR PROPHYLAXIS OF INFLAMMATORY PAIN
HUE036165T2 (hu) 2006-04-07 2018-06-28 Vertex Pharma ATP-kötõ kazetta transzportereinek modulátorai
US20080027044A1 (en) 2006-06-13 2008-01-31 Kim Lewis Prodrug antibiotic screens
CN101500611A (zh) 2006-06-23 2009-08-05 埃斯蒂维实验室股份有限公司 胆碱脂酶抑制剂与具有5-ht6受体亲和力的化合物的组合
CA2563116A1 (en) 2006-07-06 2008-01-06 Gemin X Biotechnologies Inc. Methods for treating or preventing anemia or thrombocytopenia using a triheterocyclic compound
EP1878724A1 (en) 2006-07-15 2008-01-16 sanofi-aventis A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
EP1902733A1 (en) 2006-09-19 2008-03-26 Laboratorios Del Dr. Esteve, S.A. Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
KR101504669B1 (ko) * 2006-10-19 2015-03-20 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물, 이들의 조성물 그리고 단백질 키나아제 억제제로서의 이들의 용도
TW200827340A (en) * 2006-11-10 2008-07-01 Astrazeneca Ab Chemical compounds
US8383662B2 (en) 2006-12-05 2013-02-26 National Chiao Tung University Bicyclic heteroaryl compounds
WO2008070599A1 (en) 2006-12-05 2008-06-12 Chung-Ming Sun Indazole compounds
US20080161254A1 (en) 2007-01-03 2008-07-03 Virobay, Inc. Hcv inhibitors
ES2547303T3 (es) 2007-01-19 2015-10-05 Ardea Biosciences, Inc. Inhibidores de MEK
CN101016294A (zh) 2007-03-13 2007-08-15 中国人民武装警察部队医学院 具有多种生物活性的取代吲哚－3－基草酰胺衍生物
JP2010138072A (ja) 2007-03-29 2010-06-24 Dainippon Sumitomo Pharma Co Ltd 新規な縮合ピロール誘導体
CN101687815A (zh) 2007-06-26 2010-03-31 塞诺菲-安万特股份有限公司 苯并咪唑和氮杂苯并咪唑的区域选择性铜催化合成
CN101085779A (zh) 2007-07-11 2007-12-12 中国人民武装警察部队医学院 取代吲哚－3－基草酰表鬼臼毒素衍生物及其盐及其用途
EP2018861A1 (en) 2007-07-26 2009-01-28 Laboratorios del Dr. Esteve S.A. 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain
EP2020230B1 (en) 2007-08-01 2011-01-19 Laboratorios del Dr. Esteve S.A. Combination of at least two 5-HT6-Ligands
BRPI0811317A2 (pt) 2007-08-03 2015-01-27 Summit Corp Plc Combinação, embalagem farmcêutica, kit ou mbalagem par apaciente, agente auxiliar, compsoto, usos de um agente auxiliar e de um composto, e, processo para a produção de uma combinação
AU2008287421A1 (en) 2007-08-10 2009-02-19 Glaxosmithkline Llc Nitrogen containing bicyclic chemical entities for treating viral infections
US8461177B2 (en) 2007-08-27 2013-06-11 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
US9101628B2 (en) 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
US9061010B2 (en) 2007-09-18 2015-06-23 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating a Flaviviridae family viral infection and compositions for treating a Flaviviridae family viral infection
DE102007048447A1 (de) 2007-10-10 2009-04-16 Bayer Healthcare Ag Substituierte Dihydropyrazolthione und ihre Verwendung
DE102007049157A1 (de) 2007-10-13 2009-04-16 Bayer Healthcare Ag Substituierte Dihydrotriazolone und ihre Verwendung
CN101990434B (zh) 2008-01-15 2013-07-31 西佳技术公司 用于治疗沙粒病毒感染的抗病毒药物
US7947723B2 (en) 2008-02-01 2011-05-24 Spelman College Synthesis and anti-proliferative effect of benzimidazole derivatives
JP5637982B2 (ja) 2008-04-09 2014-12-10 インフィニティー ファーマシューティカルズ， インコーポレイテッド 脂肪酸アミド加水分解酵素の阻害剤
ES2399175T3 (es) 2008-04-29 2013-03-26 Novartis Ag Derivados de imidazo-piridina como inhibidores de quinasa del receptor tipo activina (alk4 o alk5)
JP2011519858A (ja) 2008-04-30 2011-07-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラ−ゼ阻害剤
EP2300460A1 (en) 2008-05-28 2011-03-30 Wyeth LLC 3-substituted-1h-indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2009158118A2 (en) 2008-05-30 2009-12-30 University Of Notre Dame Du Lac Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria
CN102124009B (zh) 2008-07-08 2014-07-23 因特利凯公司 激酶抑制剂及其使用方法
WO2010030727A1 (en) 2008-09-10 2010-03-18 Wyeth Llc 3-substituted-1h-indole, 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US8507473B2 (en) 2008-09-11 2013-08-13 Arena Pharmaceuticals, Inc. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
GB0817576D0 (en) 2008-09-25 2008-11-05 Lectus Therapeutics Ltd Calcium ion channel modulators & uses thereof
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
EP2358202B1 (en) 2008-11-03 2016-06-15 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
WO2010068287A2 (en) 2008-12-11 2010-06-17 Angion Biomedica Corp. Small molecule modulators of hepatocyte growth factor (scatter factor) activity
TWI519530B (zh) 2009-02-20 2016-02-01 艾伯維德國有限及兩合公司 羰醯胺化合物及其作為鈣蛋白酶（ｃａｌｐａｉｎ）抑制劑之用途
US8975247B2 (en) 2009-03-18 2015-03-10 The Board Of Trustees Of The Leland Stanford Junion University Methods and compositions of treating a flaviviridae family viral infection
US20190127365A1 (en) 2017-11-01 2019-05-02 Merck Sharp & Dohme Corp. Inhibitors of hepatitis c virus replication
EP2416765B1 (en) 2009-04-06 2016-03-30 PTC Therapeutics, Inc. Hcv inhibitor and therapeutic agent combinations
US9593108B2 (en) 2009-04-06 2017-03-14 Ptc Therapeutics, Inc. Compounds and methods for antiviral treatment
WO2010117936A1 (en) 2009-04-06 2010-10-14 Schering Corporation Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent
ES2465971T3 (es) 2009-04-06 2014-06-09 University Health Network Inhibidores de quinasa y método para tratar cáncer con los mismos
JP2012522806A (ja) 2009-04-06 2012-09-27 ピーティーシー セラピューティクス，インコーポレーテッド 抗ウイルス処置のためのインドール誘導体および方法
WO2010118009A1 (en) 2009-04-06 2010-10-14 Ptc Therapeutics, Inc. Hcv inhibitor and therapeutic agent combinations
BRPI1014174B8 (pt) 2009-04-22 2021-05-25 Askat Inc uso de um composto selecionado a partir de 4-((1s)-1-{[5-cloro-2-(4-fluorofenóxi)benzoil]amino}etil)ácido benzóico, 4-[(1s)-1-({[5-cloro-2-(3-fluorofenóxi)piridin-3-il]carbonil}amino)etil]ácido benzóico e 3-[2-(4-{2-etil-4,6-dimetil-1h-imidazo[4,5-c]piridin-1-il}fenil)etil]-1-[(4-metilbenzeno)sulfonil]urea para tratamento de um câncer epitelial relacionado à pge2
US8492374B2 (en) 2009-04-29 2013-07-23 Industrial Technology Research Institute Azaazulene compounds
US8748618B2 (en) 2009-05-13 2014-06-10 University Of Virginia Patent Foundation Inhibitors of inv(16) leukemia
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
BRPI1009034A2 (pt) 2009-06-30 2019-09-24 Siga Tech Inc composição farmacêutica e método para o tratamento ou profilaxia de uma infecção viral ou doença associada a mesma
US8513433B2 (en) 2009-07-02 2013-08-20 Angion Biomedica Corp. Small molecule inhibitors of PARP activity
WO2011019738A1 (en) 2009-08-10 2011-02-17 Galenea Corporation Compounds and methods of use thereof
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
RU2012109233A (ru) 2009-09-03 2013-10-10 Аллерган, Инк. Соединения как модуляторы тирозинкиназы
AU2010331175B2 (en) 2009-12-18 2014-08-28 Mitsubishi Tanabe Pharma Corporation Novel antiplatelet agent
DK2519522T3 (en) 2009-12-30 2014-12-08 Arqule Inc SUBSTITUTED IDAZOPYRIDINYL AMINOPYRIDINE COMPOUNDS
EP2538978B1 (en) 2010-02-22 2016-09-07 RaQualia Pharma Inc. Use of an ep4 receptor antagonist in the treatment of allergic contact dermatitis and psoriasis
WO2011116176A1 (en) 2010-03-17 2011-09-22 Sirtris Pharmaceuticals Inc. 3-substitued imidazo (4, 5-b) pyridines and analogs as sirtuin modulators
JP5988506B2 (ja) 2010-04-02 2016-09-07 セノミックス インコーポレイテッド 甘味修飾物質
CN103601683B (zh) 2010-04-16 2016-03-30 中国科学院上海药物研究所 苯并杂环类化合物及其制备方法和用途
EP2571878B1 (en) 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
WO2011153310A1 (en) 2010-06-02 2011-12-08 Trius Therapeutics Dihydrofolate reductase inhibitors
WO2012003576A1 (en) * 2010-07-06 2012-01-12 Université de Montréal Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
WO2012044567A2 (en) 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Imidazole derivatives
JP5844376B2 (ja) 2010-10-06 2016-01-13 ジェイファーマ株式会社 強力な尿酸トランスポーター阻害剤の開発：それらの尿酸排泄効果のために設計された化合物
WO2012065065A1 (en) 2010-11-12 2012-05-18 Follica, Inc. Methods and compositions for modulating hair growth, wound healing and scar revision
GB201021103D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
GB201021104D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
WO2012102405A1 (ja) 2011-01-28 2012-08-02 佐藤製薬株式会社 縮環化合物
CA2825599C (en) 2011-02-01 2021-07-13 The Board Of Trustees Of The University Of Illinois 4-methyl-n-hydroxybenzamide compounds as histone deacetylase (hdac) inhibitors
RU2013138835A (ru) 2011-02-09 2015-03-20 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения в качестве ингибиторов pi3 киназы
US8791107B2 (en) 2011-02-25 2014-07-29 Takeda Pharmaceutical Company Limited N-substituted oxazinopteridines and oxazinopteridinones
CA2829558A1 (en) 2011-03-09 2012-09-13 Celgene Avilomics Research, Inc. Pi3 kinase inhibitors and uses thereof
HUE031585T2 (en) 2011-03-16 2017-07-28 Mitsubishi Tanabe Pharma Corp Sulfonamide Compounds with TRPM8 Antagonist Activity
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012126181A1 (en) 2011-03-24 2012-09-27 Ying Luo Use of kinase inhibitors in preventing and treating inflammatory disorder
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
US20130072473A1 (en) 2011-05-09 2013-03-21 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
JP5959330B2 (ja) 2011-06-17 2016-08-02 田辺三菱製薬株式会社 新規抗血小板薬
EP2763672B1 (en) 2011-10-06 2016-08-10 Merck Sharp & Dohme Corp. 1,3-substituted azetidine pde10 inhibitors
WO2013053045A1 (en) 2011-10-12 2013-04-18 Beta Pharma Canada Inc. Heterocyclic molecules as apoptosis inducers
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
US8785459B2 (en) 2011-12-27 2014-07-22 Development Center For Biotechnology Quinazoline compounds as kinase inhibitors
US20150119402A1 (en) 2012-05-08 2015-04-30 The Regents Of The University Of California Alpha 7 nicotinic acetylcholine allosteric modulators, their derivatives and uses thereof
US9550737B2 (en) 2012-06-11 2017-01-24 Ucb Biopharma Sprl TNF -α modulating benzimidazoles
LT2882440T (lt) 2012-08-07 2019-04-25 Novartis Ag Farmaciniai deriniai, apimantys b-raf slopiklį, egfr slopiklį ir nebūtinai pi3k-alfa slopiklį
WO2014047427A2 (en) 2012-09-21 2014-03-27 Vanderbilt University Substituted benzofuran, benzothiophene and indole mcl-1 inhibitors
RU2015114772A (ru) 2012-09-21 2016-11-10 Санофи Производные амида бензоимидазол-карбоновой кислоты в качестве модуляторов рецептора apj
GB201217285D0 (en) 2012-09-27 2012-11-14 Univ Central Lancashire Indole derivatives
CA2890906A1 (en) 2012-11-16 2014-05-22 The Regents Of The University Of California Pictet-spengler ligation for protein chemical modification
US9783529B2 (en) 2013-03-13 2017-10-10 Flatley Discovery Lab, Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis
US9718816B2 (en) 2013-03-15 2017-08-01 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as CARM1 inhibitors and uses thereof
CN105163761B (zh) 2013-03-19 2018-12-21 株式会社AskAt Ep4受体拮抗剂在软骨疾病的治疗中的用途
US9357781B2 (en) 2013-05-03 2016-06-07 Inscent, Inc. Honeybee repellents and uses thereof
US20160120863A1 (en) 2013-05-24 2016-05-05 Iomet Pharma Ltd. Slc2a transporter inhibitors
US10939682B2 (en) * 2013-07-02 2021-03-09 Syngenta Participations Ag Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents
HUE042111T2 (hu) 2013-07-31 2019-06-28 Merck Patent Gmbh Piridinek, pirimidinek és pirazinok mint BTK inhibitorok, továbbá ezek alkalmazása
EP3038618B1 (en) 2013-08-28 2020-10-14 Vanderbilt University Substituted indole mcl-1 inhibitors
CN104513235B (zh) 2013-09-02 2017-12-05 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EP3116506B1 (en) 2014-03-13 2019-04-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
SG11201609281UA (en) 2014-05-13 2016-12-29 Hoffmann La Roche Deuterated heterocyclic compounds and their use as imaging agents
CN105732464A (zh) 2014-12-31 2016-07-06 杏国新药股份有限公司 一种规模化生产吲哚化合物的方法
US9809539B2 (en) 2015-03-03 2017-11-07 Shuttle Pharmaceuticals, Llc Dual function molecules for histone deacetylase inhibition and ataxia telangiectasia mutated activation and methods of use thereof
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
EP3288940B9 (en) 2015-04-29 2021-07-21 Janssen Pharmaceutica NV Azabenzimidazoles and their use as ampa receptor modulators
WO2016176657A1 (en) 2015-04-30 2016-11-03 Memorial Sloan-Kettering Cancer Center Mitragynine analogs and uses thereof
WO2016196890A1 (en) 2015-06-04 2016-12-08 Vtv Therapeutics Llc Inhibitors of hexokinase and methods of use thereof
US10328063B2 (en) 2015-08-11 2019-06-25 Connexios Life Sciences Pvt. Ltd Method of wound healing
WO2017064068A1 (en) * 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
ES2811329T3 (es) 2015-11-25 2021-03-11 UCB Biopharma SRL Derivados de iminotetrahidropirimidinona como inhibidores de plasmepsina V
GB201521059D0 (en) 2015-11-30 2016-01-13 Isis Innovation Inhibitors of metallo-beta-lactamases
GB201603104D0 (en) 2016-02-23 2016-04-06 Ucb Biopharma Sprl Therapeutic agents
KR102643972B1 (ko) 2016-03-30 2024-03-07 솔루스첨단소재 주식회사 유기 발광 화합물 및 이를 이용한 유기 전계 발광 소자
SG11201808878UA (en) 2016-04-15 2018-11-29 Cancer Research Tech Ltd Heterocyclic compounds as ret kinase inhibitors
KR102491994B1 (ko) 2016-07-07 2023-01-25 브리스톨-마이어스 스큅 컴퍼니 Rock의 억제제로서의 스피로락탐
WO2018093576A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US10906890B2 (en) * 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
SG11201810611YA (en) 2016-12-22 2018-12-28 Illumina Cambridge Ltd Coumarin compounds and their uses as fluorescent labels
US11760762B2 (en) 2017-01-27 2023-09-19 Signalrx Pharmaceuticals, Inc. Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors
US11066410B2 (en) 2017-03-24 2021-07-20 3100 Central Expressway Llc Fused triazolo-pyrimidine compounds having useful pharmaceutical application
GB201708451D0 (en) 2017-05-26 2017-07-12 Univ Oxford Innovation Ltd Inhibitors of metallo-beta-lactamases
MX2019014875A (es) 2017-06-21 2021-01-29 SHY Therapeutics LLC Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
US10072045B1 (en) 2017-06-26 2018-09-11 Ramapo Pharmaceuticals, Inc. Antibacterial lipopeptides and methods for their preparation and use
CN109232362B (zh) 2017-07-10 2022-12-27 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
JP7168650B2 (ja) 2017-08-02 2022-11-09 スピノジェニックス， インコーポレイテッド ベンゾチアゾールおよび関連化合物
US11345705B2 (en) 2017-08-09 2022-05-31 Sanford Burnham Prebys Medical Discovery Institute Substituted pyrazolo[1,5-a]pyrimidines as apelin receptor agonists
IL273432B (en) 2017-09-22 2022-09-01 Kymera Therapeutics Inc Protein compounds and their uses
EP3684366A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES OF THE LATEST
BR112020007183A2 (pt) 2017-10-11 2020-09-24 Chemocentryx, Inc. tratamento de glomeruloesclerose focal segmentado com antagonistas de ccr2
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
WO2019113523A1 (en) 2017-12-08 2019-06-13 Ashok Bajji Compounds and therapeutic uses thereof
WO2019136442A1 (en) 2018-01-08 2019-07-11 Kleo Pharmaceuticals, Inc. Cd16a binding agents and uses thereof
CN112055713A (zh) 2018-03-01 2020-12-08 安娜普尔纳生物股份有限公司 用于治疗与apj受体活性有关的疾病的化合物和组合物
WO2019195118A1 (en) 2018-04-03 2019-10-10 Children's Hospital Medical Center Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension
WO2019199979A1 (en) 2018-04-10 2019-10-17 The General Hospital Corporation Antibacterial compounds
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
AU2019255196A1 (en) 2018-04-16 2020-11-12 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
CN112566666A (zh) 2018-05-14 2021-03-26 努瓦申生物公司 靶向抗癌核激素受体的化合物
MA53014A (fr) 2018-06-27 2021-05-05 Proteostasis Therapeutics Inc Composés améliorant l'activité du protéasome
CN110835333B (zh) 2018-08-16 2022-10-18 中国药科大学 苯并咪唑取代唑类化合物及其用途
KR20210061377A (ko) 2018-09-18 2021-05-27 테른스, 인크. 특정 백혈병을 치료하기 위한 화합물
JP2022511374A (ja) 2018-09-28 2022-01-31 アキュセラ インコーポレイテッド Ｖａｐ－１の阻害剤
BR112021006488A2 (pt) 2018-10-05 2021-07-06 Annapurna Bio Inc compostos e composições para o tratamento de condições associadas com atividade do receptor apj
EP3908319B1 (en) 2019-01-08 2023-10-18 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
WO2020160225A1 (en) 2019-01-30 2020-08-06 Ohio State Innovation Foundation ESTROGEN RECEPTOR BETA (ERβ) AGONISTS FOR THE TREATMENT OF FIBROTIC CONDITIONS
PE20220166A1 (es) 2019-03-05 2022-01-28 F Star Therapeutics Inc Compuestos, composiciones y metodos para el tratamiento de enfermedad
JP2022528562A (ja) 2019-04-05 2022-06-14 ストーム・セラピューティクス・リミテッド Ｍｅｔｔｌ３阻害化合物
WO2020243457A1 (en) 2019-05-29 2020-12-03 Viogen Biosciences, Llc Compounds and therapeutic uses thereof
US11136318B2 (en) 2019-06-21 2021-10-05 Noramco, Llc Processes for the preparation of aryl hydrocarbon receptor ligands
CA3157525A1 (en) 2019-10-25 2021-04-29 Gilead Sciences, Inc. Glp-1r modulating compounds
KR20210059663A (ko) 2019-11-15 2021-05-25 가천대학교 산학협력단 신규한 벤즈이미다졸 유도체 및 이의 용도
US20210300912A1 (en) 2019-12-20 2021-09-30 Ikena Oncology, Inc. Aryl hydrocarbon receptor (ahr) agonists and uses thereof
EP4097097A1 (en) 2020-01-29 2022-12-07 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2021178362A1 (en) 2020-03-03 2021-09-10 VenatoRx Pharmaceuticals, Inc. Hepatitis b capsid assembly modulators
WO2021183760A1 (en) 2020-03-11 2021-09-16 Ohio State Innovation Foundation Methods of modulating t-cell activation using estrogen receptor beta (erβ) agonists

Also Published As

Publication number Publication date
JP2022508648A (ja) 2022-01-19
EP4364798A2 (en) 2024-05-08
DK3860998T3 (da) 2024-03-25
EA202190952A1 (ru) 2021-12-22
FI3860998T3 (fi) 2024-03-27
PT3860998T (pt) 2024-04-02
US11471455B2 (en) 2022-10-18
BR112021006488A2 (pt) 2021-07-06
AR116687A1 (es) 2021-06-02
EP3860998B1 (en) 2023-12-27
US11944622B2 (en) 2024-04-02
AU2023254866A1 (en) 2023-11-16
TW202028210A (zh) 2020-08-01
EP3860998A1 (en) 2021-08-11
US20220125787A1 (en) 2022-04-28
CN113490668A (zh) 2021-10-08
KR20210125471A (ko) 2021-10-18
CA3115472A1 (en) 2020-04-09
US20230165854A1 (en) 2023-06-01
RS65335B1 (sr) 2024-04-30
IL282021A (en) 2021-05-31
AU2019353144A1 (en) 2021-05-13
AU2019353144B2 (en) 2023-11-16
WO2020073011A1 (en) 2020-04-09
MX2021003904A (es) 2021-10-26

Similar Documents

Publication Publication Date Title
ZA201908154B (en) Compounds and compositions for treating conditions associated with nlrp activity
IL283042A (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS RELATED TO NLRP ACTIVITY
IL280331A (en) Tricyclic compounds to inhibit the activity of SHP2
PT3468972T (pt) Compostos e composições para inibir a atividade da shp2
IL282021A (en) Compounds and compositions for the treatment of conditions associated with APJ receptor activity
IL277272A (en) Rimgepent for CGRP-related disorders
KR102223657B9 (ko) 염증성 장질환 예방 또는 치료용 약학적 조성물
IL272061A (en) Preparations for the treatment of stress-related disorders
PL3765646T3 (pl) Kompozycja stali
SG11202102349PA (en) Compositions and methods for treating disorders ameliorated by muscarnic receptor activation
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
IL269743A (en) Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions
GB2598463B (en) Improved methods for angiography
GB201911187D0 (en) Receptor
GB2541102B (en) Extension piece for drain hoppers
IL261774B (en) Compositions for treating dermatological conditions
SG11202008959RA (en) Composition for improving skin conditions
PT3810128T (pt) Composições para tratar e/ou prevenir doenças de agregação de proteinas
SG11202010911WA (en) Methods and compositions for treating chronic urticaria
EP3430893C0 (de) Anordnung zur verhinderung der passage von tieren
HUP1800129A1 (hu) A miozin-2-izoformákat szelektíven gátló, gyógyászatilag hatásos vegyületek
KR102324922B9 (ko) 오스테오칼신을 포함하는 염증성 질환의 예방 또는 치료용 약학 조성물
KR102388028B9 (ko) 폴리펩타이드 전달용 조성물
HUP1800227A2 (hu) Keresztalj
IL279550A (en) Ingredients and methods for treating trichomonas